ARUP is a national and academic, nonprofit reference laboratory with advanced hematology testing.

new

ARUP at ASH 2022

 
circle-x

CME and Education

 
notification

Hematopathologists

 
notification

ARUP Tests

 

Visit us at booth #3629 to consult with our renowned hematopathologists, discover educational resources from ARUP Consult® and the ARUP Institute for Learning, and learn about our extensive test menu.

Sign up to receive a free copy of “WHO and ICC: A Quick Guide to the Classification of Hematolymphoid Tumors."

Sign up to receive a free copy of “WHO and ICC: A Quick Guide to the Classification of Hematolymphoid Tumors."

Let’s Connect: Meet Our Hematopathologists

Our hematopathologists provide consultations on difficult-to-diagnosis cases, including appropriate testing and result interpretation.

notification Schedule: Experts at Our Booth


The following hematopathologists will be available at booth 3629 for discussion at the specified times:

Saturday, December 10

11:00 AM–12:30 PM
Peng Li, MD, PhD
Madhu P. Menon, MD, PhD, FCAP
Robert S. Ohgami, MD, PhD
Jay L. Patel, MD, MBA

1:30–2:00 PM
Jay L. Patel, MD, MBA
Abdulrahman Saadalla, MB, BCh

3:30–4:00 PM
Tracy I. George, MD
Archana Mishra Agarwal, MD
Madhu P. Menon, MD, PhD, FCAP
Jay L. Patel, MD, MBA
 

Sunday, December 11

11:00 AM–12:30 PM
Tracy I. George, MD
Kristi J. Smock, MD

Monday, December 12

10:00–10:30 AM
Tracy I. George, MD

notification ARUP Workshop


Friday, December 9, 2022, 291–292 (Ernest N. Morial Convention Center), 2:44 PM:

Early Detection of DDX41 Related Myeloid Neoplasm Using Immunophenotypic Profiling By Flow Cytometry
Peng Li, MD, PhD

notification ARUP Presentations


Sunday, December 11, 2022, Session: 634. 217–219 (Ernest N. Morial Convention Center)

  • 4:30 PM: Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study
    Deepti H. Radia, MRCPI, FRCPath, Tracy I. George, MD, et al.
  • 4:45 PM: Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)
    Daniel J. DeAngelo, MD, PhD, Tracy I. George, MD, Jay L. Patel, MD, et al.

Sunday, December 11, 2022, Session: 101. 243–245 (Ernest N. Morial Convention Center)

  • 1:15 PM: Congenital Erythrocytosis Due to Novel CMTR1K769L Mutation Has Augmented Hypoxia Signaling and Features of Both Primary and Secondary Erythrocytosis
    Jihyun Song, PhD, Rong Mao, MD, et al.

circle-x ARUP Posters

Saturday, December 10, 2022, 5:30–7:30 PM, Hall D (Ernest N. Morial Convention Center)

Session 101:

  • Next Generation Sequencing for the Diagnosis of Hereditary Hemolytic Anemias Including Pyruvate Kinase Deficiency: Report from a No-Cost Diagnostic Program
    Jorune Balciuniene, PhD, Archana M. Agarwal, MD, et al.

Session 301:

  • The Lupus Anticoagulant Titer Is Associated with Elevated Anti-Phosphatidyl-Serine/Prothrombin Antibody Levels
    Abdulrahman Saadalla, MB, BCh, et al.

Session 614:

  • A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1
    Erin Guest, MD, Rodney R. Miles, MD, PhD, et al.

Session 634:

  • An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety
    Daniel J. DeAngelo, MD, PhD, Tracy I. George, MD, et al.
  • FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients
    Srdan Verstovsek, MD, PhD, Tracy I. George, MD, Jay L. Patel, MD, et al.

Sunday, December 11, 2022, 6:00–8:00 PM, Hall D (Ernest N. Morial Convention Center)

Session 621:

  • Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
    Robert J. Hayashi, Rodney R. Miles, MD, et al.

Session 631:

  • Clonal Dynamics of ASM-AHN with Avapritinib Treatment
    Xiaomeng Huang, PhD, Tracy I. George, MD, et al.

Session 634:

  • Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
    Cem Akin, MD, PhD, Tracy I. George, MD, et al.
  • AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis
    Daniel J. DeAngelo, MD, PhD, Tracy I. George, MD, et al.

Monday, December 12, 2022, 6:00–8:00 PM, Hall D (Ernest N. Morial Convention Center)

Session 637:

  • Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features
    Anthony Hunter, MD, Tracy I. George, MD, et al.